Floatz logo

Eplontersen

Transthyretin Amyloid Cardiomyopathy

AstraZenecaPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Transthyretin Amyloid Cardiomyopathy cohort.

Asset / SponsorPhaseRating
fx-1006a
Pfizer
Phase 4BB
Empagliflozin
Columbia University
Phase 4BB
Coramitug
Novo Nordisk A/S
Phase 1CC
TECHNETIUM TC 99M PYROPHOSPHATE
Mayo Clinic
Early Phase 1CC

Same molecule, other indications

Eplontersen is also rated in:

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Dormant
CCC
Indicative ·
53 / 100
View asset →
Healthy VolunteersDormant
CCC
Indicative ·
48 / 100
View asset →
familial visceral amyloidosisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →